NCT04529525View on ClinicalTrials.gov

Ivermectin to Prevent Hospitalizations in COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

February 22, 2021

Study Completion Date

February 22, 2021

Conditions
Covid19
Interventions
DRUG

Ivermectin

Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.

DRUG

Placebo

Patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.

Trial Locations (1)

3400

Ministry of Public Health of the Province of Corrientes, Corrientes

All Listed Sponsors
lead

Instituto de Cardiología de Corrientes

OTHER

NCT04529525 - Ivermectin to Prevent Hospitalizations in COVID-19 | Biotech Hunter | Biotech Hunter